Amarantus Bioscience Neurorestoration Animal Data Presentation to be Webcast Live Today from OneMedForum 2013 at 4:40pm Eastern
SUNNYVALE, Calif., Jan. 8, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments for diseases associated with protein misfolding and apoptosis, today announced that Dr. John W. Commissiong, CSO will present results of its MANF Parkinson's disease neurorestoration animal studies at the OneMedForum SF 2013 conference on Tuesday, January 8, 2013 at 4:40pm ET. The presentation will be webcast live at the link: http://onemedplace.com/forum/webcast/. Advisor Dr. Joseph Rubinfeld will follow Dr. Commissiong's data presentation, and briefly discuss MANF's potential in areas beyond Parkinson's disease.
OneMedForum SF 2013 is an international healthcare conference where emerging private and small cap public companies present to, and meet with investors of all types including high net worth individuals, alternative investors, asset managers, hedge funds, institutional investors, and venture capitalists.
Dr. John Commissiong, Chief Scientific Officer
Dr. Commissiong has served as the Chief Scientific Officer and a Director of Amarantus since co-founding the Company in 2008. Dr. Commissiong was Head of the Neurotrophic Factors Group and the Neural Transplantation lab at the National Institute of Neurological Disorders and Stroke. He has an over 30 year career in researching disorders of the Central Nervous System. Dr. Commissiong's lab discovered MANF in 2003. The work pioneered by Dr. Commissiong has led to significant advancements in the field of astrocyte-neuron biology. Dr. Commissiong believes understandind astrocyte-neuron biology will lead to a new generation of therapies brought to market for the treatment brain-related disorders. Dr. Commissiong holds a Ph.D. in Neurophysiology from the University of Southampton.
Dr. Joseph Rubinfeld, Advisor
Dr. Rubinfeld is one of the four original co-founders of Amgen. Dr. Rubinfeld co-founded Amgen after a 23 year career in a variety of senior scientific and operational positions at Bristol Myers Squibb. Dr. Rubinfeld served as a Senior Director at Cetus Corporation from 1987 to 1990 until co-founded SuperGen in 1991, and served as its President & CEO through 2003. Dr. Rubinfeld is credited with inventing Amoxicillin, biodegradeable detergent and polaroid film. Dr. Rubinfeld received his PhD in Chemistry from Columbia University.
A link to bios of executives on the Amarantus Board of Advisors can be found here: http://www.amarantus.com/about-us/corporate-advisory-board.html
Established in 2008, OneMedForum is the conference component of OneMedPlace, which provides an integrated media platform to showcase the best ideas and innovations in health and medicine globally. The media platform also includes: OneMedRadio; OneMedTV, OneMedSentinel; a global database of companies; and OneMedResearch, which tracks promising lesser-known microcap public companies. For more information visit the conference website. www.onemedforum.com
About Amarantus Bioscience, Inc.
Amarantus Bioscience, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation. This press release does not represent an offer to buy or sell securities.
Amarantus Bioscience, Inc.
IR Sense, LLC
SOURCE Amarantus Bioscience, Inc.
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.